Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 144.40
Bid: 144.60
Ask: 145.00
Change: -0.40 (-0.28%)
Spread: 0.40 (0.277%)
Open: 138.00
High: 145.00
Low: 138.00
Prev. Close: 144.80
ELM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q3 Trading Update

26 Oct 2022 07:00

RNS Number : 0982E
Elementis PLC
26 October 2022
 

26 October 2022.

Elementis plc

Q3 Trading Update

Trading in line with expectations - outlook unchanged

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues a trading update for the three months ended 30 September 2022.

Third quarter business performance

 

The Group delivered a good performance in the third quarter, with double-digit revenue growth on an underlying basis, driven by further strong performances in Personal Care and Coatings, where the focus on innovation, new product development and new business opportunities, underpinned by strong key account relationships and supply resiliency, continued to deliver sales growth. The Chromium business also performed well in the quarter whilst the Talc business continued to be impacted by weakness in European markets.

 

Overall the Group saw strong performances in the Americas, with lower demand in Europe and continuing market weakness in China. The full year outlook for the Group remains unchanged.

 

· Coatings delivered a solid third quarter performance. Pricing actions continued to offset raw material and energy cost increases and protect margins. Sales growth was driven by new business wins at key accounts and market share gains, with new products gaining further traction The business remains on track to deliver full year performance significantly ahead of last year.

 

· Personal Care continued to perform strongly in the third quarter, with market demand and pricing actions in both Cosmetics and AP Actives driving strong sales growth and margin expansion versus the prior year period. Whilst normal seasonality and some moderation of demand is expected in the fourth quarter, the business is expected to deliver full year performance substantially ahead of last year.

 

· Talc performance in the third quarter was impacted by continuing weaker demand in European end markets, in particular automotive, reduced ceramics demand in China, and the loss of sales into Russia and neighbouring countries. Higher energy and logistics costs, as well as adverse currency movements, were offset by new business wins and price increases which will continue to be implemented through the rest of the year.

· Chromium sales in the third quarter were ahead of the prior year period, reflecting solid demand and price increases. Global industry utilization remains high, with improved pricing and lower chrome ore prices offsetting higher energy and logistics costs. An update on the strategic review of the Chromium business is expected around the calendar year end, as previously indicated.

 

Outlook

 

The full year outlook for the Group remains unchanged, with Group leverage lower.

 

Despite weakening underlying macro-economic conditions creating further headwinds, particularly in Europe, the Group's continued focus on innovation and new business opportunities, along with further pricing actions and operating efficiencies, is expected to deliver full year financial performance in line with our expectations.

 

 

 

Commenting on the third quarter performance, CEO, Paul Waterman said,

"We delivered a good third quarter performance, with our focus on product innovation, customer relationships, value pricing and operating efficiency continuing to create real momentum in our business. This is enabling us to weather the macroeconomic headwinds affecting a number of our markets, and deliver sales growth and margin expansion in line with our expectations.

We expect the market environment to remain challenging, but are confident that by continuing to execute effectively on our strategy we will make further progress towards achieving our medium-term goals."

 

Enquiries

Elementis plc

David Boyd, Investor Relations Tel: 0207 067 2994

David.boyd.ext@elementis.com Mob:+44 7764 905135

 

Tulchan

Martin Robinson Tel: 020 7353 4200

Olivia Peters

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTMABLTMTATBBT
Date   Source Headline
3rd May 202411:46 amRNSHolding(s) in Company
1st May 202410:06 amRNSTotal Voting Rights
30th Apr 202411:36 amRNSResult of AGM
30th Apr 20247:00 amRNSFirst quarter trading update
29th Apr 202412:13 pmRNSResponse to open letter from Gatemore
12th Apr 202411:33 amRNSDirector/PDMR Shareholding
12th Apr 202411:28 amRNSDirector/PDMR Shareholding
9th Apr 20246:04 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSAnnual Financial Report & Notice of AGM
19th Mar 20243:02 pmRNSAdditional Listing
15th Mar 20241:00 pmRNSDirectorate Change
12th Mar 20244:38 pmRNSDirector/PDMR Shareholding
12th Mar 20244:33 pmRNSDirector/PDMR Shareholding
8th Mar 20245:56 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirectorate changes
7th Mar 20247:00 amRNSPreliminary results year ended 31 December 2023
1st Mar 20249:30 amRNSBlock listing Interim Review
18th Jan 20247:00 amRNSTrading Update
2nd Jan 20249:45 amRNSTotal Voting Rights
1st Dec 202310:46 amRNSTotal Voting Rights
30th Nov 20239:38 amRNSDirector/PDMR Shareholding
14th Nov 20237:00 amRNS2023 Capital Markets Day
1st Nov 20239:46 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company
1st Sep 20239:49 amRNSBlock listing Interim Review
1st Sep 20239:42 amRNSTotal Voting Rights
1st Aug 20239:44 amRNSTotal Voting Rights
27th Jul 20232:16 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSHalf-year Report
20th Jul 202312:58 pmRNSHolding(s) in Company
3rd Jul 202310:21 amRNSTotal Voting Rights
29th Jun 20234:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20239:32 amRNSDirector/PDMR Shareholding
30th May 20238:06 amRNSDirector Declaration
2nd May 20239:37 amRNSTotal Voting Rights
26th Apr 20232:12 pmRNSResult of AGM
26th Apr 20237:00 amRNSAGM Trading Statement
17th Apr 202310:15 amRNSDirector/PDMR Shareholding
17th Apr 202310:10 amRNSDirector/PDMR Shareholding
13th Apr 20234:24 pmRNSDirector/PDMR Shareholding
3rd Apr 202311:28 amRNSDirector Declaration
3rd Apr 20239:34 amRNSTotal Voting Rights
24th Mar 20239:27 amRNSDirector/PDMR Shareholding
22nd Mar 20234:02 pmRNSAnnual Financial Report & Notice of AGM
17th Mar 20232:58 pmRNSAdditional Listing
14th Mar 20237:30 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.